SNY

Sanofi ADR

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Sanofi ADR (SNY) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Value (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C-
Factor Score 1.9 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 2.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 23.2
EV / EBITDA 8.2
Rev Growth YoY 6.0%
Gross Margin 72.4%
Price Return 3M -2.4%
Price Return 12M -7.7%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 2.2
ROE 6.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-03 C- (1.9) C (2.4) B (3.2) C (2.4) C- (2.0) C (2.4)